Agenda-setting intelligence, analysis and advice for the global fashion community.
AstraZeneca Plc agreed to pay Chinese company CSPC Pharmaceutical Group Ltd. as much as $18.5 billion for its obesity drug candidates, as the British drugmaker tries to push into the growing weight-loss market.
Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice. Or get in touch at support@businessoffashion.com if you experience difficulties.




